Halozyme Therapeutics Inc risk profile
33 Normal where most of the sector sits
Measured 21 October 2026 from HALO's filed statements. Recomputed nightly.
33 (Normal), driven by Concentration at 64, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 24 | Normal | Stable | One-year price volatility — 38.1% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | 10 | Contained | Easing | Capital spending against operating cash — 0.01x |
| Leverage and coverage | 26 | Normal | Worsening | Net debt to EBITDA — 4.18x |
| Competitive position | 24 | Normal | Stable | R&D-intensity gap against peers — -10.6 percentage points |
| Concentration | 64 | Stretched | Stable | Customer concentration — 2,262 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Halozyme Therapeutics Inc